Immune Checkpoint Inhibitors Concept

subject area of

• A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies  Journal Articles
• A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner  Journal Articles
• A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk  Journal Articles
• A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer  Journal Articles
• A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors  Journal Articles
• Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma  Journal Articles
• Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?  Journal Articles
• Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma  Journal Articles
• Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma  Journal Articles
• Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade  Journal Articles
• Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review  Journal Articles
• Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer  Journal Articles
• Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer  Journal Articles
• Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer  Journal Articles
• Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors  Journal Articles
• Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors  Journal Articles
• De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors  Journal Articles
• Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies  Journal Articles
• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial  Journal Articles
• Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer  Journal Articles
• Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events  Journal Articles
• Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy  Journal Articles
• Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells  Journal Articles
• Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition  Journal Articles
• Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens  Journal Articles
• Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer  Journal Articles
• Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients  Journal Articles
• Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.  Journal Articles
• Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer  Journal Articles
• No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors  Journal Articles
• Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?  Journal Articles
• Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review  Journal Articles
• Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy  Journal Articles
• Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response  Journal Articles
• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial  Journal Articles
• Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma  Journal Articles
• Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer  Journal Articles
• Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer  Journal Articles
• Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases  Journal Articles
• Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors  Journal Articles
• Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer  Journal Articles
• Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy  Journal Articles
• Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients  Journal Articles
• Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers  Journal Articles
• The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer  Journal Articles
• The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review  Journal Articles
• Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline  Journal Articles
• Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis  Journal Articles
• Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers  Journal Articles
• Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study  Journal Articles
• Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors  Journal Articles